Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma

NCT05269355 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.

NCT NCT05269355
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05269355 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma
Lead sponsor
PTC Therapeutics
Phase
Phase 2/3
Overall status
Terminated
Start date
May 23, 2022
Completion date
July 17, 2024
Enrollment
359 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

leiomyosarcoma